Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

172 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-07-31

Study Completion Date

2009-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the outcomes of treating epidemic keratoconjunctivitis with 2% povidone-iodine.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis

NCT01363700

Allergic Conjunctivitis

COMPLETED PHASE3

Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Viral Conjunctivitis

NCT03749317

Adenoviral Conjunctivitis

COMPLETED PHASE2

Povidone-iodine 2% Eye Drop Versus Artificial Tear Drop for Treatment of Adenoviral Keratoconjunctivitis

NCT04041856

Adenoviral Keratoconjunctivitis

UNKNOWN PHASE1/PHASE2

A Long-term Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis

NCT01363713

Allergic Conjunctivitis

COMPLETED PHASE3

Combination Treatment of 5% Natamycin and 1% Voriconazole in Fungal Keratitis

NCT03230058

Infection, Fungal

UNKNOWN PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study design was a prospective interventional case series. Our institutional ethical committee approved the study protocol in April 2004. We performed this study between July 2004 and December 2009. During this period, there were 2 episodes of EKC epidemic. The first episode was in 2006 and the second in 2009.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Viral Conjunctivitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

2% povidone-iodine

Group Type EXPERIMENTAL

2% povidone-iodine

Intervention Type DRUG

apply 4 times a day for one week

2% povidone-iodine

Intervention Type DRUG

apply 2% povidone-iodine 4 times per day for one week

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

2% povidone-iodine

apply 4 times a day for one week

Intervention Type DRUG

2% povidone-iodine

apply 2% povidone-iodine 4 times per day for one week

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

PVP-I PVP-I

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients who were diagnosed with EKC at the outpatient ophthalmic unit

Exclusion Criteria

* children younger than six years
* women being pregnant or during lactation
* history of allergy to povidone-iodine
* prior ocular surgery
* contact lens usage and chronic eye diseases with current eye medications.

Minimum Eligible Age

7 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No